News Releases

Pfenex Inc. to Present at the Jefferies 2017 London Healthcare Conference

SAN DIEGO, Nov. 9, 2017 /PRNewswire/ -- Pfenex Inc. (NYSE AMERICAN: PFNX), announced today that it will be presenting at the Jefferies 2017 London Healthcare Conference on Wednesday, November 15th at 12:40 pm GMT / 7:40 pm ET. The presentation will be webcast and available for replay in the Investors Section of Pfenex's website at www.pfenex.com.

Pfenex logo (PRNewsFoto/Pfenex)

Pfenex investors and others should note that we announce material information to the public about the Company through a variety of means, including our website (http://www.pfenex.com/),  our investor relations website (http://pfenex.investorroom.com/), press releases, SEC filings, public conference calls, corporate Twitter account (https://twitter.com/pfenex), Facebook page (https://www.facebook.com/Pfenex-Inc-105908276167776/timeline/), and LinkedIn page (https://www.linkedin.com/company/pfenex-inc) in order to achieve broad, non-exclusionary distribution of information to the public and to comply with our disclosure obligations under Regulation FD. We encourage our investors and others to monitor and review the information we make public in these locations as such information could be deemed to be material information. Please note that this list may be updated from time to time.

About Pfenex Inc.

Pfenex Inc. is a clinical-stage biotechnology company developing complex therapeutic proteins. Using the patented Pfenex Expression Technology® platform, the Company has created an advanced pipeline of therapeutic equivalents, vaccines, biologics and biosimilars. The Company's lead product candidates are PF708, a therapeutic equivalent candidate to Forteo® (teriparatide) for the treatment of osteoporosis, and its novel anthrax vaccine candidates, Px563L and RPA563, funded through an advanced development contract with the US government. In addition, Pfenex is developing hematology/oncology products in collaboration with Jazz Pharmaceuticals. Furthermore, the Company's pipeline includes biosimilar candidates to Lucentis® and Neulasta®

 

SOURCE Pfenex Inc.

For further information: Company: Pfenex Investor Relations, (858) 352-4400, InvestorRelations@pfenex.com


print email rss